ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
115.50
-1.48 (-1.27%)
At close: Mar 13, 2026, 4:00 PM EDT
119.76
+4.26 (3.69%)
Pre-market: Mar 16, 2026, 6:25 AM EDT
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 639.00K EUR in the quarter ending September 30, 2025, a decrease of -88.61%. This brings the company's revenue in the last twelve months to 5.31M, down -42.89% year-over-year. In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M with 135.94% growth.
Revenue (ttm)
5.31M EUR
Revenue Growth
-42.89%
P/S Ratio
1,442.60
Revenue / Employee
79,269 EUR
Employees
67
Market Cap
8.99B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
| Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
| Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
| Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
| Dec 31, 2020 | 14.00K | 21.00K | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Exelixis | 2.32B |
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Axsome Therapeutics | 638.50M |
| ImmunityBio | 113.29M |
| Cytokinetics | 88.04M |
ABVX News
- 3 days ago - Abivax (ABVX) Shares Surge Amid Denial of AstraZeneca Takeover Report - GuruFocus
- 3 days ago - Abivax spokesperson denies takeover rumors reported by French media - Reuters
- 3 days ago - AstraZeneca (AZN) Obtains Exclusive Negotiation Period with Abivax - GuruFocus
- 3 days ago - AstraZeneca (AZN) Engages in Exclusive Takeover Talks with Abivax - GuruFocus
- 3 days ago - AstraZeneca (AZN) Enters Exclusive Agreement Boosting Abivax Shares - GuruFocus
- 4 days ago - Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline - Benzinga
- 4 days ago - Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline - Benzinga
- 4 days ago - Harbor Health Care ETF Q4 2025 Portfolio Review - Seeking Alpha